• MeSH
• Adult MeSH
• Glaucoma * physiopathology   therapy   MeSH
• Graves Ophthalmopathy * diagnosis   classification   therapy   MeSH
• Middle Aged MeSH
• Humans MeSH
• Intraocular Pressure MeSH
• Ocular Hypertension * pathology   therapy   MeSH
• Oculomotor Muscles physiopathology   MeSH
• Strabismus MeSH
• Treatment Outcome MeSH
• Check Tag
• Adult MeSH
• Middle Aged MeSH
• Humans MeSH
• Male MeSH
• Female MeSH
• Publication type
• Case Reports MeSH
• Review MeSH

• Keywords
• dystyreoidní optická neuropatie,
• MeSH
• Cytokines MeSH
• Diagnosis, Differential MeSH
• Graves Disease MeSH
• Graves Ophthalmopathy * diagnosis   classification   physiopathology   therapy   MeSH
• Hashimoto Disease MeSH
• Immunoglobulins MeSH
• Hyaluronic Acid MeSH
• Humans MeSH
• Lymphocytes MeSH
• Thyroid Diseases immunology   classification   complications   MeSH
• Optic Nerve Diseases MeSH
• Ocular Motility Disorders MeSH
• Receptors, Thyrotropin agonists   antagonists & inhibitors   MeSH
• Risk Factors MeSH
• Thyroidectomy MeSH
• Ultrasonography MeSH
• Check Tag
• Humans MeSH
• Publication type
• Review MeSH

Endokrinní nebo také Graves-Basedowova orbitopatie (EO) je závažná, progresivní oční komplikace asociovaná s autoimunitním onemocněním štítné žlázy. Typickými příznaky jsou retrakce horního víčka, periorbitální edém, porucha pohyblivosti očního bulbu, diplopie, zánětlivý otok měkkých tkání orbity vedoucí k protruzi oka a ve vážnějších případech až ztráta zraku v důsledku útlaku zrakového nervu či poškození rohovky. Standardem léčby je kortikoterapie, podání per os je limitováno nežádoucími účinky, proto je upřednostňováno podání v podobě intravenózního pulzu. V roce 2016 bylo vydáno jednotné doporučení European Thyroid Association a European Group on Graves´ Orbithopaty (EUGOGO) pro endokrinní orbitopatii a také doporučení American Thyroid Association pro léčbu hypertyreózy, které zahrnuje léčbu EO.

Endocrine or Graves-Basedow Orbitopathy (EO) is a serious, progressive ocular complication associated with autoimmune thyroiddisease. Typical symptoms include upper eyelid retraction, periorbital edema, bulb disorder, diplopia, inflammation of the orbitalsoft tissue leading to the eye-ball protrusion and in more serious cases, loss of vision due to optic nerve suppression or cornealdamage. The standard of treatment is corticotherapy, the administration of per os is limited by the side effects, therefore intravenouspulses are preferred. In 2016, a single recommendation was issued by the European Thyroid Association and the EuropeanGroup on Graves Orbithopathies (EUGOGO) for Endocrine Orbitopathy, as well as the recommendations of the American ThyroidAssociation for the Treatment of Hyperthyroidism, which mentions the treatment of EO.

• MeSH
• Graves Ophthalmopathy * diagnosis   classification   physiopathology   therapy   MeSH
• Adrenal Cortex Hormones therapeutic use   MeSH
• Immunologic Factors therapeutic use   MeSH
• Humans MeSH
• Rituximab therapeutic use   MeSH
• Practice Guidelines as Topic MeSH
• Check Tag
• Humans MeSH
• Publication type
• Research Support, Non-U.S. Gov't MeSH

• MeSH
• Adult MeSH
• Graves Ophthalmopathy * drug therapy   classification   MeSH
• Middle Aged MeSH
• Humans MeSH
• Methylprednisolone * administration & dosage   adverse effects   MeSH
• Placebos therapeutic use   MeSH
• Prospective Studies MeSH
• Pulse Therapy, Drug methods   adverse effects   MeSH
• Aged MeSH
• Treatment Outcome MeSH
• Check Tag
• Adult MeSH
• Middle Aged MeSH
• Humans MeSH
• Aged MeSH
• Publication type
• Overall MeSH